avillionllp.com Open in urlscan Pro
66.29.135.51  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
+44 (0)203 764 9530 avillion@avillionllp.com Contact

Avillion

Primary Menu
 * Partnerships
 * An Innovative Model
 * The Team
 * Business Opportunity
 * Our Investors
 * News


ACCELERATING GLOBAL DRUG DEVELOPMENT THROUGH SUCCESSFUL PARTNERING FOR PATIENT
BENEFIT

Scroll to learn more


WHAT WE DO

Our objective is to enable our partners to continue to develop their most
important drug candidates without increasing the burden on their P&L or cash
reserves

Avillion will finance 100% of studies within the partnership

Help to accelerate the development of late phase drugs in the pipeline

Provide a team of expert professionals with extensive experience

Let us help you with your project


WHY CHOOSE AVILLION?


INCREASED SHOTS ON GOAL

Fund phase II and III studies on the registrational path for a specific asset


EXPANDED GEOGRAPHIES

Overcome regional limitations, such as budget constraints or conflicting
priorities as a result of lack of expertise or footprint


BROADENED PIPELINE

Finance studies for external assets that are being acquired (M&A) or in-licensed


NETWORKS, FOCUSED ON EXECUTION

Obtain access to broad networks, focused execution and delivery

Ready to take your pharmaceutical project to the next stage?

Contact Us


LATEST NEWS

31May
2022
US FDA accepts New Drug Application filed by Avillion for AstraZeneca’s PT027
for the as-needed treatment or prevention of symptoms in asthma patients
16May
2022
Avillion announces publication of positive full results from MANDALA Phase III
trial of AstraZeneca’s PT027 in asthma patients in the New England Journal of
Medicine
09Sep
2021
Avillion announces positive results in MANDALA and DENALI Phase III trials of
AstraZeneca’s PT027, a fixed-dose combination of albuterol and budesonide,
demonstrating significant benefits for asthma patients
10May
2021
JPM ranked Avillion #61 in the top 200 Female-Powered Private Businesses in the
UK – April 2021
23Apr
2021
Avillion’s positive Phase 2 trial of tri-specific Nanobody® sonelokimab (M1095)
in chronic psoriasis published in The Lancet
01Apr
2021
OxSonics Appoints Dr Allison Jeynes as Chair of the Board

View all news


ACCESS GLOBAL NETWORKS

 * Global staff
   presence

 * Global staff
   presence

 * Global staff
   presence

 * Global staff
   presence

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Global staff
   presence

 * Global staff
   presence

 * Global staff
   presence

 * Global staff
   presence

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

 * Worldwide
   clinical trials

   
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 

Read about our global outreach

Avillion

 * Partnerships
 * Governance
 * Areas of interest

 * An Innovative Model
 * Operational Excellence
 * Study Delivery
 * Case Study

 * Business Opportunity
 * What we do
 * Global outreach
 * Frequently Asked Questions

Contact

+44 (0)203 764 9530 avillion@avillionllp.com Linkedin


© Avillion LLP. Registered in England and Wales No: OC379058

Privacy Policy | Cookie Policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in
settings.

Accept Reject Settings
cookie settings
Close GDPR Cookie Settings
 * Cookie Overview
 * Required Cookies
 * Operational Cookies
 * Privacy Policy

Cookie Overview


Cookies are small text files that are placed on your device when you visit a
website. Cookies may be used to keep track of pages visited within the site,
help you continue where you left off or remember your preferences, such as
language settings.
Cookies help us to make online services easier to use, monitor the use of our
site and help us improve the service provided to you.

TYPES OF COOKIES
Cookies can be “persistent” or “session” cookies. Persistent cookies remain on
your device for a period of time when you go offline, while session cookies are
deleted as soon as you close your web browser.

COOKIE PREFERECNES
You may change your preferences at any time or withdraw your consent for each
cookie category - except Required cookies using this website’s cookie setting
option.

Required Cookies

Required cookies (persistent) should be enabled at all times so that we can save
your cookie preferences.

These cookies are essential to enable you to move around the website and use its
features.

Enable or Disable Cookies
Operational Cookies

These cookies (which can be persistent or session) collect information about how
visitors use a website, for instance which pages visitors go to most often and
if they receive error messages. They are used to improve how a website works in
future versions, e.g. Google Analytics, Microsoft Clarity.

Enable or Disable Cookies

Please enable required cookies first so that we can save your preferences!

Privacy Policy

More information about our Privacy Policy

Enable All Save Changes